Company news
Turn Therapeutics Inc. news in 2026
Turn Therapeutics Inc.'s news releases, calls and decks from 2026, newest first.
Turn Therapeutics to Present at Jefferies Global Healthcare Conference in London
November 16, 2026
Turn Therapeutics Provides Corporate Updates and Reports Third Quarter 2026 Financial Results
November 9, 2026
Turn Therapeutics’ GX-03 Earns “Developmental Immunology Solution of the Year” in 2026 BioTech Breakthrough Awards Program
November 5, 2026
U.S. Bancorp | BTIG to Host Turn Therapeutics for Virtual Fireside Chat
October 21, 2026
Turn Therapeutics to Present at Stifel 2026 Virtual Immunology and Inflammation Forum
September 10, 2026
Turn Therapeutics Appoints Former CDC Director Robert R. Redfield, M.D., as Chief Scientific Officer
September 9, 2026
Turn Therapeutics Announces New Peer-Reviewed Research Showing GX-03 Selectively Reduces Key Drivers of Skin Inflammation and Itch
August 20, 2026
Turn Therapeutics Provides Corporate Updates and Reports Second Quarter 2026 Financial Results
August 12, 2026
Turn Therapeutics to Ring the Nasdaq Closing Bell on Monday, August 10, 2026
July 28, 2026
Turn Therapeutics Announces Final Stage 2 Design and Data-Driven Expansion of GX-03 Phase 2 Program in Atopic Dermatitis
July 7, 2026
Turn Therapeutics to Host Webcast Presenting Comprehensive Interim Analysis and Optimized Stage 2 Design for GX-03 in Atopic Dermatitis
July 6, 2026
Turn Therapeutics Reports Interim Analysis Findings and Adaptive Optimization Strategy from Phase 2 GX-03 Trial in Moderate-to-Severe Atopic Dermatitis
June 1, 2026
Turn Therapeutics Announces Peer-Reviewed Publication in Journal of Dermatological Treatment Highlighting GX-03 Activity in IL-36 Associated Inflammatory Model
May 27, 2026
Turn Therapeutics Appoints Physician-Scientist and Former FDA Commissioner, Dr. Stephen M. Hahn, as Executive Clinical and Regulatory Lead
May 18, 2026
Turn Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Updates
May 11, 2026
Turn Therapeutics Reports Full Year 2025 Financial Results and Provides Corporate Updates
March 30, 2026
Turn Therapeutics Secures Up to $25 Million in Financing From Avenue Capital Group
March 23, 2026
Turn Therapeutics Appoints Dr. Robert Redfield as Senior Advisor of Health Policy and Regulatory Affairs
February 17, 2026
Turn Therapeutics to Present at Upcoming TD Cowen and Oppenheimer Healthcare Conferences
February 9, 2026
Turn Therapeutics Announces Corporate and Pipeline Updates and 2026 Outlook Ahead of the 44th Annual J.P. Morgan Healthcare Conference
January 12, 2026
Turn Therapeutics Appoints Martin Dewhurst to its Board of Directors
January 7, 2026
Decks in 2026
- Investor Presentation (November 2026)
Investor deck · 37 slides · Nov 10, 2026
- Investor Presentation (October 2026)
Investor deck · 37 slides · Oct 7, 2026
- Investor Presentation (July 2026)
Investor deck · 38 slides · Jul 28, 2026
- Investor Presentation (July 2026)
Investor deck · 25 slides · Jul 7, 2026
- 2026 Jefferies Global Healthcare Conference
Conference · 28 slides · Jun 3, 2026
- Investor Presentation (February 2026)
Investor deck · 31 slides · Feb 9, 2026
- Investor Presentation (January 2026)
Investor deck · 27 slides · Jan 7, 2026